In a war zone or on the road an accident can cause extreme and painful damage to the human body. While the external injuries are visible and are treated by paramedics that arrive on-site, it is often the internal injuries that cause complications, and in some instances even loss of life. Z-Medica, a prolific tech solution provider assists healthcare providers, military personnel, first responders, and consumers around the world. It provides them with products that offer control over blood clots, and temporarily eliminates hemorrhaging problems. QuikClot, the flagship hemostatic device that Z-Medica produces and deploys is capable of stopping bleeding in emergency cases, and of keeping a victim safe until proper treatment can be administered to them. The key differentiating factor of this medical piece is the presence of kaolin, an agent that is proven to accelerate natural congealing of blood.
Z-Medica solicits their services and products to a variety of industries that provide emergency medical services such as law enforcement, first responders, hospitals and the armed forces. The company’s QuikClot device assists first responders to control blood loss in a victim facing a life or death situation. The apparatus can be used similarly to standard gauze, and it helps reduce expensive treatments while establishing patient stability until they receive the next level of treatment. At hospitals, they can be utilized to provide an efficient hemostatis solution for emergency cases in the trauma care sector. The use of the product is not limited, and staff at medical centers can use QuikClot in other departments such as critical care, dermatology, and cardiology, to name a few. The easy adaptability of the device is attributed to the structure of the product as it comes in various sizes enabling its easy transferability and portability.
The QuikClot product is also leveraged in more severe scenarios by personnel in the defense arena; it helps keep soldiers wounded in battle alive by aiding them not to bleed out until help arrives.
QuikClot, the flagship hemostatic device that Z-Medica produces and deploys is capable of stopping bleeding in emergency cases, and of keeping a victim safe until proper treatment can be administered to them
Z-Medica not only is supporting the process of saving lives, but it is also very careful about its product portfolio and technology, the company has multiple patents to protect their innovations in the hematology services space.
Z-Medica’s success is credited to their team of highly proficient management personnel that have extensive experience of soliciting and developing innovative bleeding control products around the world. The company is headed by Eric Compton, CEO, who has help prestigious C-Level posts at other organizations in the medical tech arena. Along with the team of highly trained professionals and medical practitioners, Z-Medica is pushing forward to bring better solutions that offer more stability and intuitiveness in the field of hemostatis.
For the future, the company plans to increase its product portfolio, and expects to reach more areas where its technology and services can be used. Besides the QuikClot device, Z-Medica offers another product called Quikclot Control+. This device is a hemostatis apparatus that elevates the capabilities of its parent product, and it can temporarily control internal organ space bleeding in patients showing signs of class III or class injuries. Z-Medica hopes to successfully bring these options to the forefront of the medical industry space and wishes to be the world leader in the injury correction arena.
Z-Medica Appoints Chris Van Gorder, FACHE, to Board of Directors
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: